Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer
Jennifer L. Hope, Yijuan Zhang, Hannah A. Faso, Evelyn S. Sanchez-Hernández, Beatrice Silvestri, Brianna J. Smith, Sanmati H. Nakil, Sreeja Biswas Roy, Michelle P. Lin, Ashley B. Palete, Swetha Maganti, Lily Ling, Dennis C. Otero, Katelyn T. Byrne, Gabriele Romano, , Linda M. Bradley
This study shows that disabling PSGL-1 enhances anti-tumor immunity in pancreatic cancer by improving CD8+ T cell function and response to PD-1 blockade.
bioRxiv · May 22, 2025 · PreprintImmunology